ArticleDiscover oncology2025
Causal association between rheumatoid arthritis and pancreatic cancer: a bidirectional two-sample Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveElucidating the causal relationship between rheumatoid arthritis (RA) and pancreatic cancer (PC) remains methodologically challenging due to limitations inherent in observational studies. This study applied a bidirectional two-sample Mendelian randomization (MR) design to investigate the potential causal interplay between RA and PC, aiming to uncover shared pathogenic pathways and genetic predispositions through comprehensive instrumental variable analysis.
methodsUtilizing genome-wide association study (GWAS) meta-analysis data, we systematically screened and incorporated independent single nucleotide polymorphisms (SNPs) associated with RA and PC as instrumental variables. The primary analytical approach was the inverse-variance weighted fixed-effects model (IVW-FE). To ensure methodological rigor and validate causal inferences, we complemented this with several approaches: simple median, weighted median, and MR-Egger regression. Heterogeneity was assessed using Cochran's Q test, and pleiotropy was evaluated using MR-Egger intercept analysis. Sensitivity analysis was conducted using the leave-one-out approach. All effect estimates are reported as odds ratios (ORs) with corresponding 95% confidence intervals (CIs).
resultsSeventy-seven SNPs met the predefined inclusion criteria. MR analyses revealed that elevated genetic susceptibility to RA was causally associated with an increased risk of PC (OR = 1.187, 95% CI = 1.355-1.039, P = 0.011). MR-Egger regression analysis indicated no significant pleiotropic effects (intercept p = 0.434). Cochran's Q statistics indicated no substantial heterogeneity in the causal estimates for RA (P = 0.064). Consistent with these findings, leave-one-out sensitivity analyses confirmed the absence of influential outlier variants in the instrumental variable sets. However, there was no significant causal association between PC and the risk of RA (OR = 0.991, 95% CI = 0.957-1.027, P = 0.620).
conclusionsOur results support a unidirectional causal relationship, identifying RA as a potential risk factor for the development of pancreatic cancer, with no evidence for a reverse causal effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.